title: [Second-line therapy for Helicobacter pylori].
abstract: Currently, the recommended second-line eradication regimen for Helicobacter pylori is a quadruple therapy consisting of PPI, bismuth, tetracycline and metronidazole. Recently, levofloxacin-based (PPI, levofloxacin and amoxicillin) and moxifloxacin-based (PPI, moxifloxacin and amoxicillin) triple therapy represent promising alternative. In Japan, PPI-based triple therapy (PPI, amoxicillin and metronidazole) is used for second-line regimen after failure of first-line eradication. The rate of second-line eradication is still high(approximately 90% (ITT)) and triple therapy with PPI, AMPC, and MNZ may still be considered useful for second-line eradication therapy of Helicobacter pylori in Japan. High-dose dual therapy with PPI and amoxicillin for 2 weeks may be useful treatment strategy after failure of first-line eradication.
authors: Department of Gastroenterology, Juntendo University, School of Medicine.
authors: Daisuke
authors: D
authors: Asaoka
authors: Akihito
authors: A
authors: Nagahara
authors: Mariko
authors: M
authors: Hojo
authors: Hitoshi
authors: H
authors: Sasaki
authors: Sumio
authors: S
authors: Watanabe
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007348:Insurance, Health / Q000191:economics; D007564:Japan; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents